arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Taysha Gene Therapies, Inc.

TSHA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$3.81
▼ -7.5% Today
as of Oct 23, 09:52 ET
Last 30 days -23.56% Sep 14 → Oct 23
$3.38 $3.86 $4.33 $4.81 $5.29 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$4.07
High
$4.17
Low
$3.94
Volume
$3M
Avg Vol
$3M
Mkt Cap
$1.4B
P/E (TTM)
—
Beta
—
52w High
$7.30
52w Low
$3.46
Div Yield
—
Shares Out
$325M

Recent Press Releases & News last 60 days · 7 items

Oct 19 · 02:07 Simply Wall St.
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Oct 9 · 18:12 Simply Wall St.
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Oct 9 · 07:15 Simply Wall St.
Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
▸ Show all 7 press releases & news Free account →

TSHA earnings at a glance

Taysha Gene Therapies, Inc. (TSHA) is scheduled to report earnings on Tuesday, November 3, 2026 — in 11 days. Analysts expect earnings per share of -$0.14, compared with -$0.09 in the same quarter last year (-56%). The options market is pricing a move of about ±29.3% after the report, a range of roughly $2.69 to $4.93 from today's $3.81. Over its last 6 reports the stock rose the next day 4 times and fell 2, moving ±4.1% on average; after the most recent report on Aug 11, 2026 it moved -4.1%. That means options currently expect more movement than TSHA has typically delivered. TSHA beat the consensus EPS estimate in 1 of its last 6 reported quarters. Implied volatility is currently 248%. The share price of $3.81 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.46
$7.30
9% of range
Avg surprise (last 6)
-6.6%
Avg reaction (last 6)
+1.4%
67% positive
Latest IV / EM
248%
EM ±29.3% · $4 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.93$-0.72$-0.50$-0.29$-0.07 Actual $-0.28Actual $-0.38Actual $-0.93Actual $-0.10Actual $-0.09Actual $-0.10Actual $-0.08Est $-0.08Actual $-0.09Est $-0.07Actual $-0.09Est $-0.09Actual $-0.08Est $-0.11Actual $-0.12Est $-0.10Actual $-0.13Est $-0.11 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-47M$-34M$-22M$-10M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 11, 2026Jun/2026 $-0.13 $-0.11 -18.2% -22.2% -4.1% earnings
Wed May 6, 2026Mar/2026 $-0.12 $-0.10 -20.0% -50.0% +0.6% earnings
Thu Mar 19, 20268K 2026-03-19 $-0.08 $-0.11 +27.3% — +2.5% earnings
Tue Nov 4, 2025Sep/2025 $-0.09 $-0.09 0.0% — -4.3% earnings
Tue Aug 12, 2025Jun/2025 $-0.09 $-0.07 -28.6% — +5.4% earnings
Thu May 15, 2025Mar/2025 $-0.08 $-0.08 0.0% — +8.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.10 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.09 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.10 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.93 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.38 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.28 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Tue Nov 3, 2026Sep/2026OTHER -$0.14-$0.09 -55.6%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$0$2M$2M—$2M
Cost of revenue————————
Gross profit————————
Operating income$-47M$-43M—$-34M$-27M$-21M—$-26M
Net income$-47M$-42M—$-33M$-27M$-22M—$-26M
EPS (diluted)$-0.13$-0.12—$-0.09$-0.09$-0.08—$-0.10

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$455M$277M$320M$297M$313M$117M$139M$158M
Inventory————————
Total current assets$461M$282M$325M$300M$316M$121M$142M$162M
Total assets$470M$300M$343M$317M$333M$138M$160M$180M
Long-term debt$49M$49M$50M$51M$41M$42M$44M$43M
Total liabilities$83M$88M$96M$98M$85M$83M$89M$91M
Total equity$387M$212M$247M$219M$249M$55M$72M$89M

Implied volatility — last 90 days

52%144%236%328%421% Jun 08 — IV 198% · EM ±26.1%Jun 09 — IV 216% · EM ±27.1%Jun 10 — IV 188% · EM ±22.2%Jun 11 — IV 134% · EM ±14.8%Jun 17 — IV 251% · EM ±10.5%Jun 19 — IV 107% · EM ±23.8%Jun 22 — IV 117% · EM ±24.5%Jun 23 — IV 123% · EM ±25.1%Jun 24 — IV 197% · EM ±39.4%Jun 25 — IV 113% · EM ±22.1%Jun 26 — IV 109% · EM ±20.9%Jun 29 — IV 111% · EM ±19.7%Jun 30 — IV 115% · EM ±19.8%Jul 01 — IV 110% · EM ±18.4%Jul 02 — IV 99% · EM ±16.1%Jul 03 — IV 103% · EM ±16.1%Jul 06 — IV 102% · EM ±14.1%Jul 07 — IV 102% · EM ±13.5%Jul 08 — IV 166% · EM ±20.8%Jul 09 — IV 126% · EM ±14.8%Jul 10 — IV 150% · EM ±16.5%Jul 13 — IV 310% · EM ±25.9%Jul 15 — IV 164% · EM ±9.7%Jul 16 — IV 421% · EM ±17.6%Jul 20 — IV 112% · EM ±26.4%Jul 21 — IV 118% · EM ±27.3%Jul 22 — IV 112% · EM ±25.6%Jul 23 — IV 118% · EM ±26.6%Jul 24 — IV 98% · EM ±21.7%Jul 27 — IV 115% · EM ±23.9%Jul 28 — IV 107% · EM ±22.0%Jul 29 — IV 156% · EM ±31.3%Jul 30 — IV 106% · EM ±20.9%Jul 31 — IV 125% · EM ±23.9%Aug 03 — IV 137% · EM ±24.2%Aug 04 — IV 108% · EM ±18.5%Aug 05 — IV 130% · EM ±21.7%Aug 06 — IV 129% · EM ±20.9%Aug 07 — IV 127% · EM ±19.8%Aug 10 — IV 142% · EM ±19.6%Aug 11 — IV 143% · EM ±18.9%Aug 12 — IV 92% · EM ±11.6%Aug 13 — IV 167% · EM ±19.8%Aug 14 — IV 125% · EM ±13.9%Aug 17 — IV 106% · EM ±8.9%Aug 18 — IV 257% · EM ±18.6%Aug 19 — IV 316% · EM ±18.7%Aug 20 — IV 235% · EM ±9.8%Aug 24 — IV 74% · EM ±15.5%Aug 25 — IV 73% · EM ±14.9%Aug 26 — IV 58% · EM ±11.6%Aug 27 — IV 56% · EM ±10.9%Aug 31 — IV 84% · EM ±14.9%Sep 01 — IV 92% · EM ±15.8%Sep 02 — IV 127% · EM ±21.3%Sep 03 — IV 146% · EM ±23.7%Sep 04 — IV 149% · EM ±23.2%Sep 07 — IV 168% · EM ±23.2%Sep 08 — IV 180% · EM ±23.8%Sep 09 — IV 254% · EM ±31.8%Sep 21 — IV 97% · EM ±20.3%Sep 22 — IV 93% · EM ±19.0%Sep 23 — IV 112% · EM ±22.4%Sep 28 — IV 115% · EM ±20.3%Sep 29 — IV 52% · EM ±9.0%Sep 30 — IV 74% · EM ±12.3%Oct 01 — IV 130% · EM ±21.1%Oct 02 — IV 111% · EM ±17.3%Oct 06 — IV 188% · EM ±24.8%Oct 08 — IV 248% · EM ±29.3%

Sector peers

INBX
Inhibrx Biosciences, Inc.
$1.4B $94.68-3.6%
MAZE
Maze Therapeutics, Inc.
$1.5B $31.31-3.9%
IMCR
Immunocore Holdings plc
$1.5B $31.34-2.3%
REPL
Replimune Group, Inc.
$1.2B $11.61-0.9%
IMTX
Immatics N.V.
$1.1B $7.36-4.3%
VOR
Vor Biopharma Inc.
$1.1B $18.43-2.7%

TSHA earnings FAQ

When is TSHA's next earnings date?

Taysha Gene Therapies, Inc. is expected to report on November 3, 2026.

What is TSHA's expected move for earnings?

Options currently price a move of about ±29.3%, or $1.12 per share either way from $3.81.

How does TSHA stock usually react to earnings?

Across the last 6 reports the average next-day move was ±4.1%, up 4 times and down 2 times.

What EPS are analysts expecting from Taysha Gene Therapies, Inc.?

The consensus estimate is -$0.14 per share, versus -$0.09 a year ago.

What is TSHA's implied volatility?

TSHA's at-the-money implied volatility is about 248% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in